VAXESS TECHNOLOGIES INC
Medtech · Private
Microneedle array patch (MIMIX platform) for sustained-release delivery of GLP-1 receptor agonists
vaxess.com →- Grants
- $8.6M
- 15 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $749K
- 1 award · Health and Human S
- #348 of 4531 in medtech
- Patents
- 33
- 0 granted · 33 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Silk: A New Approach to Developing a Heat-stable Rotavirus Vaccine | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Silk-Stabilized Inactivated Polio Vaccine | $210,066 | |
| Federal grant | Department of Health and Human Services · Phase I · Silk-based biospecimen stabilization for exposure assessment diagnostics | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Silk-based biospecimen stabilization for exposure assessment diagnostics | $225,000 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: A New Approach to Developing a Heat-stable Rotavirus Vaccine | $1,409,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Silk-Based Blood Sample Stabilization for Prostate Cancer Diagnostics | $223,416 | |
| Federal grant | Department of Health and Human Services · Phase I · Silk-Based Blood Sample Stabilization for Prostate Cancer Diagnostics | $223,416 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Silk-based biospecimen stabilization for exposure assessment diagnostics | $1,499,990 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Silk-based biospecimen stabilization for exposure assessment diagnostics | $749,994 | |
| Federal grant | Department of Health and Human Services · Phase II · Silk-based biospecimen stabilization for exposure assessment diagnostics | $749,996 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Influenza Vaccine Efficacy Through Infection Mimicry | $299,698 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: At home, single dose mRNA vaccine patch (COVID-19) | $256,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Influenza Vaccine Efficacy Through Infection Mimicry | $997,500 | |
| Federal contract | Department of Health and Human Services · Vaxess - Mimix-covid Pre-fusion Spike Protein Vaccine Patch Mfg: Scaling To 100M Units Of Shelf-stable, Self-applied, Single-dose Vaccine | $749,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Influenza Vaccine Efficacy Through Infection Mimicry | $999,900 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Needle Free Microarray Patch for Delivery of a GLP-1 Receptor Agonist | $335,410 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 345 | NanoEngineering Corporation | $753K | $1.4M |
| 346 | RESOURCEPATH LLC | $750K | — |
| 347 | CHARLOT BIOSCIENCES INC | $750K | — |
| 348 | VAXESS TECHNOLOGIES INC | $749K | — |
| 349 | LifeCanvas Technologies Inc. | $738K | — |
| 350 | PACIFIC OPTICA, INC. | $734K | — |
| 351 | TRANSGENOMIC, INC. | $732K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Microneedle Array Patches (maps), Systems, And Methods For Manufacturing And Using Sameapplication
- Compositions And Devices For Vaccine Release And Uses Thereofapplication
- Vaccine Formulations With Increased Stabilityapplication
- Silk Fibroin-based Microneedles And Uses Thereofapplication
- Polymer-based Biospecimen Collection Devices And Uses Thereofapplication
- Microneedle Comprising Silk Fibroin Applied To A Dissolvable Baseapplication
- Vaccine Formulations With Increased Stabilityapplication
- Microneedle Compositions Comprising Copovidone for Delivery of mRNAapplication
- Applicator For Medicament Patchapplication
- Applicator For Medicament Patchapplication
- Microneedle Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)application
- Compositions And Devices For Vaccine Release And Uses Thereofapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.